Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 277 across all filing types
Latest filing 2023-07-31 Remuneration Information
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
PDMR Shareholding/Share Incentive Plan
Remuneration Information Classification · 99% confidence The document is a notification filed via RNS (RNS Number: 7804H) dated July 31, 2023. The content explicitly details share purchases and matched share awards made by Persons Discharging Managerial Responsibilities (PDMRs) pursuant to employee share incentive plans (SIP Schemes). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (Code: DIRS), which is often mandated by regulations like Article 19(1) of MAR (Regulation (EU) No. 596/2014), as referenced in the tables. Although it is distributed via RNS, the specific content is about insider trades, making DIRS the most accurate classification.
2023-07-31 English
Trading Update and Notice of Results
Earnings Release Classification · 98% confidence The document is titled 'Diaceutics PLC - Trading Update and Notice of Results' and provides key financial highlights for the six months ended 30 June 2023 (H1 2023), including revenue growth (32%), order book growth (43%), and cash position. It explicitly states that the company 'will report unaudited results for the six months ended 30 June 2023 on 26 September 2023.' This structure—a summary of performance for a recent interim period followed by a notice of the full results release date—is characteristic of an Earnings Release (ER). It is not the comprehensive Interim Report (IR) itself, nor is it a full Annual Report (10-K). Since it announces key performance indicators ahead of the formal results, ER is the most appropriate classification. H1 2023
2023-07-25 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is an RNS announcement dated June 29, 2023, detailing share purchases by PDMRs (Persons Discharging Managerial Responsibilities) under an Employee Benefit Trust/Share Incentive Plan (SIP). The key content is the notification of transactions by directors/executives (Susanne Munksted, Jordan Clark, Julie Browne, Nick Roberts). This directly corresponds to the definition of Director's Dealing (insider trades). Reviewing the definitions: - 10-K/AR/IR: Not a full financial report. - ER/MRQ: Not an earnings release. - CT: Not a call transcript. - DVA: Not voting results. - DIV/CAP/SHA/POS: Not dividend, financing, or general share issue announcements, but specific insider transactions. - DIRS (Director's Dealing): Matches perfectly as it reports personal share transactions by company directors and executives. The document structure (RNS Number, PDMR Shareholding header, Article 19(1) notification tables) confirms it is a regulatory filing specifically about insider transactions.
2023-06-29 English
Purchase and Sale of Shares and PDMR Shareholdings
Director's Dealing Classification · 100% confidence The document is an official announcement filed via RNS (RNS Number: 7228B) dated June 6, 2023. The content explicitly details a 'Purchase and Sale of Shares and PDMR Shareholdings' involving the CFO, Nick Roberts. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of Director's Dealing. The regulatory context mentioned (Article 19(1) of Regulation (EU) No. 596/2014) confirms this is an insider transaction disclosure. Therefore, the appropriate code is DIRS.
2023-06-06 English
Group of companies' accounts made up to 2022-12-31
Regulatory Filings
2023-06-06 English
USD 10.1 million multi-year enterprise engagement
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and is dated '05 June 2023'. It announces a significant business event: a US$10.1 million multi-year enterprise engagement with a top 10 global pharma company. The text explicitly states, 'This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law... and is disclosed in accordance with the Company's obligations under Article 17 of MAR.' The presence of the RNS header, the disclosure under MAR (Market Abuse Regulation), and the nature of the announcement (a material business contract award) strongly indicate this is a regulatory news service release. Since it is a general announcement of material information that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing fallback, RNS. FY 2023
2023-06-05 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.